Sakar Healthcare Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Sakar Healthcare.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	18.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

No updates

Recent updates

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Mar 23

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Mar 02

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Feb 08

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Jan 10

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Dec 14

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

Nov 22

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sakar Healthcare has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NSEI:SAKAR - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	1,518	125	N/A	N/A	N/A
9/30/2023	1,480	144	-475	163	N/A
6/30/2023	1,438	127	N/A	N/A	N/A
3/31/2023	1,342	128	-489	333	N/A
12/31/2022	1,302	178	N/A	N/A	N/A
9/30/2022	1,265	139	-568	352	N/A
6/30/2022	1,265	144	N/A	N/A	N/A
3/31/2022	1,291	152	-109	246	N/A
12/31/2021	1,139	80	N/A	N/A	N/A
9/30/2021	1,109	97	-284	368	N/A
6/30/2021	1,054	118	N/A	N/A	N/A
3/31/2021	953	107	-210	146	N/A
12/31/2020	913	118	N/A	N/A	N/A
9/30/2020	870	122	-219	-50	N/A
6/30/2020	884	106	N/A	N/A	N/A
3/31/2020	839	96	55	189	N/A
12/31/2019	851	88	N/A	N/A	N/A
9/30/2019	844	86	N/A	N/A	N/A
6/30/2019	744	78	N/A	N/A	N/A
3/31/2019	688	67	-88	161	N/A
3/31/2018	534	38	-35	53	N/A
3/31/2017	447	34	N/A	20	N/A
3/31/2016	414	22	N/A	92	N/A
12/31/2015	386	24	N/A	38	N/A
3/31/2015	350	18	N/A	42	N/A
3/31/2014	297	18	N/A	86	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if SAKAR's forecast earnings growth is above the savings rate (6.7%).

Earnings vs Market: Insufficient data to determine if SAKAR's earnings are forecast to grow faster than the Indian market

High Growth Earnings: Insufficient data to determine if SAKAR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if SAKAR's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if SAKAR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SAKAR's Return on Equity is forecast to be high in 3 years time

Sakar Healthcare Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Investor sentiment deteriorates as stock falls 15%

Third quarter 2024 earnings released: EPS: ₹0.98 (vs ₹2.16 in 3Q 2023)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Second quarter 2024 earnings released: EPS: ₹1.68 (vs ₹1.01 in 2Q 2023)

Insufficient new directors

Investor sentiment improves as stock rises 20%

New major risk - Financial position

First quarter 2024 earnings released: EPS: ₹1.46 (vs ₹1.65 in 1Q 2023)

New major risk - Share price stability

Sakar Healthcare Limited announced that it expects to receive INR 599.999123 million in funding from Tata Investment Corporation Limited

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improves as stock rises 27%

Sakar Healthcare Limited, Annual General Meeting, Sep 21, 2023

Full year 2023 earnings released: EPS: ₹6.59 (vs ₹8.90 in FY 2022)

Is Sakar Healthcare (NSE:SAKAR) A Risky Investment?

Third quarter 2023 earnings released: EPS: ₹2.16 (vs ₹0.07 in 3Q 2022)

Here's Why Sakar Healthcare (NSE:SAKAR) Has Caught The Eye Of Investors

Investor sentiment improved over the past week

Is Sakar Healthcare (NSE:SAKAR) Using Too Much Debt?

Second quarter 2023 earnings released: EPS: ₹1.01 (vs ₹1.44 in 2Q 2022)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: ₹1.65 (vs ₹1.80 in 1Q 2022)

Sakar Healthcare Limited, Annual General Meeting, Sep 20, 2022

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Full year 2022 earnings released: EPS: ₹8.73 (vs ₹7.09 in FY 2021)

Investor sentiment improved over the past week

Sakar Healthcare (NSE:SAKAR) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹1.44 (vs ₹3.04 in 2Q 2021)

Full year 2021 earnings released: EPS ₹7.09 (vs ₹6.43 in FY 2020)

Investor sentiment deteriorated over the past week

With EPS Growth And More, Sakar Healthcare (NSE:SAKAR) Is Interesting

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹6.87 (vs ₹6.43 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Might Deserve Your Attention Today

Insider Buying: The Sakar Healthcare Limited (NSE:SAKAR) Chairman & MD Just Bought 7.1% More Shares

Has Sakar Healthcare Limited's (NSE:SAKAR) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Third quarter 2021 earnings released: EPS ₹1.20 (vs ₹1.48 in 3Q 2020)

Does Sakar Healthcare (NSE:SAKAR) Have A Healthy Balance Sheet?

Investor sentiment improved over the past week

New 90-day high: ₹107

Here's Why I Think Sakar Healthcare (NSE:SAKAR) Is An Interesting Stock

Market bids up stock over the past week

New 90-day high: ₹91.65

Should You Rely On Sakar Healthcare's (NSE:SAKAR) Earnings Growth?

First half earnings released

Market pulls back on stock over the past week

New 90-day high: ₹84.85

New 90-day high - ₹78.70

First quarter earnings released

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies